Alcon announces commercial launch of its Intraocular Lens for Presbyopia

Alcon, Inc. announces to launch its +3.0 Add Power AcrySof® ReSTOR® Aspheric IOL during the European Society of Cataract and Refractive Surgeons in annual meeting in Berlin, Germany.

Kevin Buehler, senior vice president, global markets and chief marketing officer,

"Advanced technology IOLs that correct for presbyopia or astigmatism are the fastest growing segment in the IOL market. The addition of the +3.0 Add Power AcrySof® ReSTOR® Aspheric IOL provides surgeons with an additional IOL option to meet the clinical needs of their patients and further enhances our leadership position in this category."

Alcon completed its CE Mark of the +3.0 Add Power AcrySof® ReSTOR® Aspheric IOL during the third quarter of 2007 and is now available in most major markets outside the United States.

Clinical trial results demonstrated that the +3.0 Add Power AcrySof® ReSTOR® Aspheric IOL optimally manages light energy delivered to the retina regardless of the lighting situation to provide patients with high resolution image quality and minimal visual disturbances. At the three-month follow-up exam, 95 percent of patients had combined distance corrected visual acuities (near, intermediate and distance) of 20/40 or better. The clinical studies also showed a high rate of patient satisfaction with 96 percent of patients stating that they would have this lens implanted again.
Some of its services are:

AcrySof® Intraocular Lenses. they are the most frequently implanted lenses in the world, with more than 35 million implants since their introduction in the early 1990s. Alcon’s AcrySof® IOLs offer cataract patients a variety of benefits that give cataract patients a full range of quality vision. Also the company is dedicated in businesses like researches, development, manufacturing and pharmaceutical marketing, surgical equipment and devices, contact lens care solutions and other vision care products that treat diseases, disorders and other conditions of the eye.

Source: ACL

Related?

Leave a Reply


Protected by Comment Guard Pro